Speed bump

Speedel Holding Ltd. says that even though it halted Phase III testing of SPP301 for diabetic nephropathy, it doesn't think it is the final curtain for the endothelin receptor antagonist. The company says feedback from its DSMB, which is privy to the unblinded data, suggests that there may be a way forward.

Nevertheless, the decision will take about six months and could leave Speedel with a gap at the top of its pipeline.

Speedel (SWX:SPPN, Basel, Switzerland) halted the ASCEND trial the week before Christmas because

Read the full 852 word article

How to gain access

Continue reading with a
two-week free trial.